11/03/2015 : THERADIAG strengthens its positioning in the oncology theranostics market with its Herceptin® monitoring test receiving CE marking

Croissy-Beaubourg and Montpellier, March 11, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today it has received CE marking for the Herceptin® (trastuzumab) monitoring test that expend its Lisa Tracker range.

Herceptin®/trastuzumab is a humanized monoclonal antibody designed to block tumor growth by interfering with the HER2 receptor. Trastuzumab is the 3rd most used treatment in oncology, mainly applied for the treatment of metastatic breast cancer and metastatic gastric cancer. Herceptin® generated $6.5 billions dollars in sales over 2013.

This is the 9th CE-marking obtained by Theradiag for its Lisa Tracker range in the last few years. It adds a 3rd oncology monitoring test to the Lisa Tracker portfolio – the market’s most comprehensive range of biotherapy monitoring kits.

Professor Gérard Tobelem, M.D., Chairman of Theradiag and former Chairman of France’s National Blood Bank concludes: “Cancer patient care is facing the dual challenge of improving treatments through the development of personalized medicine while decreasing the healthcare spending. The biotherapy monitoring tools developed by Theradiag meet both of these objectives. They allow physicians to tailor treatments to the patients’ needs with a fast, reliable and precise blood test”.


About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer and HIV/AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.

For more information about Theradiag, please visit our website: www.theradiag.com


Investor Relations

Nathalie Trepo

+33 1 64 62 10 12



Financial communications/ investor relations

Valentine Brouchot/

Pierre Laurent

+33 1 44 71 94 94


Alize RP


Caroline Carmagnol

+33 6 64 18 99 59